Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals is dedicated to developing therapies for endocrine diseases, focusing on underserved patients. They emphasize innovation and discovery to improve symptoms and quality of life. The company also supports medical education, research projects, and awareness initiatives through grants and investigator-initiated studies, fostering advancements in disease awareness and patient care.
Industries
Nr. of Employees
medium (51-250)
Patents
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
US-12280046-B2
View DetailsCompositions and methods for administering paltusotine to patients with hepatic impairment
US-12208092-B2
View DetailsSomatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
US-12134610-B2
View Details
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
US-12280046-B2
View DetailsCompositions and methods for administering paltusotine to patients with hepatic impairment
US-12208092-B2
View DetailsSomatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
US-12134610-B2
View DetailsProducts
Oral SST2-selective small-molecule agonist (clinical-stage)
Clinical-stage orally administered small-molecule selective for somatostatin receptor subtype 2 intended to modulate hormone pathways as an alternative to injectable therapies for acromegaly and carcinoid syndrome.
Oral ACTH (MC2R) antagonist (clinical-stage)
Orally administered antagonist of ACTH signaling developed to modulate ACTH-driven cortisol production for conditions such as congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
Non-peptide drug conjugate for receptor-expressing tumors
Preclinical candidate non-peptide drug conjugate designed to deliver a cytotoxic payload to tumors expressing a target receptor, intended for neuroendocrine tumors and other receptor-positive malignancies.
Receptor-targeted radiotherapeutic development platform
Platform approach to develop targeted radiotherapeutic agents intended to deliver radionuclide therapy to tumor-specific targets across multiple solid tumor types.
Pipeline of receptor-subtype selective small-molecule modulators
Clinical and preclinical candidates targeting additional receptor subtypes developed for indication-specific endocrine and metabolic disorders.
Oral SST2-selective small-molecule agonist (clinical-stage)
Clinical-stage orally administered small-molecule selective for somatostatin receptor subtype 2 intended to modulate hormone pathways as an alternative to injectable therapies for acromegaly and carcinoid syndrome.
Oral ACTH (MC2R) antagonist (clinical-stage)
Orally administered antagonist of ACTH signaling developed to modulate ACTH-driven cortisol production for conditions such as congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
Non-peptide drug conjugate for receptor-expressing tumors
Preclinical candidate non-peptide drug conjugate designed to deliver a cytotoxic payload to tumors expressing a target receptor, intended for neuroendocrine tumors and other receptor-positive malignancies.
Receptor-targeted radiotherapeutic development platform
Platform approach to develop targeted radiotherapeutic agents intended to deliver radionuclide therapy to tumor-specific targets across multiple solid tumor types.
Pipeline of receptor-subtype selective small-molecule modulators
Clinical and preclinical candidates targeting additional receptor subtypes developed for indication-specific endocrine and metabolic disorders.
Services
Review and provision of product and/or financial support for investigator-initiated clinical studies, including scientific rationale review, budget evaluation, contracting and distribution under executed agreements.
Administration of medical education grant awards to accredited providers, including needs assessment, budget review, compliance with accreditation standards and award contracting.
Operational management of patient advisory councils and engagement activities to capture patient perspectives for development programs, including recruitment, contracting, meeting facilitation and privacy-protected capture of input.
Development and distribution of patient-facing educational content explaining clinical trial types, phases, informed consent, safety monitoring and participation options; includes links to external registries and recruitment resources.
Preparation and dissemination of scientific posters, presentations and conference materials to report clinical and preclinical data at medical meetings.
Production of investor webcasts, R&D presentations and public materials to communicate program status and strategic updates to shareholders and scientific stakeholders.
Review and provision of product and/or financial support for investigator-initiated clinical studies, including scientific rationale review, budget evaluation, contracting and distribution under executed agreements.
Administration of medical education grant awards to accredited providers, including needs assessment, budget review, compliance with accreditation standards and award contracting.
Operational management of patient advisory councils and engagement activities to capture patient perspectives for development programs, including recruitment, contracting, meeting facilitation and privacy-protected capture of input.
Development and distribution of patient-facing educational content explaining clinical trial types, phases, informed consent, safety monitoring and participation options; includes links to external registries and recruitment resources.
Preparation and dissemination of scientific posters, presentations and conference materials to report clinical and preclinical data at medical meetings.
Production of investor webcasts, R&D presentations and public materials to communicate program status and strategic updates to shareholders and scientific stakeholders.
Expertise Areas
- Small-molecule therapeutic discovery and preclinical-to-clinical development
- Targeted payload delivery (drug conjugates and radiotherapeutics) platform development
- IND-enabling nonclinical study assembly and candidate selection
- Clinical trial design and operational management (Phase I–III)
Key Technologies
- Structure-guided ligand design
- Oral non-peptide small-molecule receptor modulators
- Small-molecule drug conjugation chemistries
- Receptor-targeted radionuclide delivery methods